Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11483
Title: Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
Authors: Grace, Josephine A;Herath, Chandana B;Mak, Kai Yan;Burrell, Louise M;Angus, Peter W
Affiliation: Department of Medicine, The University of Melbourne, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia. j.grace4@pgrad.unimelb.edu.au
Issue Date: 1-Aug-2012
Citation: Clinical Science (london, England : 1979); 123(4): 225-39
Abstract: The RAS (renin-angiotensin system) is now recognized as an important regulator of liver fibrosis and portal pressure. Liver injury stimulates the hepatic expression of components of the RAS, such as ACE (angiotensin-converting enzyme) and the AT(1) receptor [AngII (angiotensin II) type 1 receptor], which play an active role in promoting inflammation and deposition of extracellular matrix. In addition, the more recently recognized structural homologue of ACE, ACE2, is also up-regulated. ACE2 catalyses the conversion of AngII into Ang-(1-7) [angiotensin-(1-7)], and there is accumulating evidence that this 'alternative axis' of the RAS has anti-fibrotic, vasodilatory and anti-proliferative effects, thus counterbalancing the effects of AngII in the liver. The RAS is also emerging as an important contributor to the pathophysiology of portal hypertension in cirrhosis. Although the intrahepatic circulation in cirrhosis is hypercontractile in response to AngII, resulting in increased hepatic resistance, the splanchnic vasculature is hyporesponsive, promoting the development of the hyperdynamic circulation that characterizes portal hypertension. Both liver fibrosis and portal hypertension represent important therapeutic challenges for the clinician, and there is accumulating evidence that RAS blockade may be beneficial in these circumstances. The present review outlines new aspects of the RAS and explores its role in the pathogenesis and treatment of liver fibrosis and portal hypertension.
Internal ID Number: 22548407
URI: http://ahro.austin.org.au/austinjspui/handle/1/11483
DOI: 10.1042/CS20120030
URL: http://www.ncbi.nlm.nih.gov/pubmed/22548407
Type: Journal Article
Subjects: Angiotensin II.genetics
Angiotensin II Type 1 Receptor Blockers.therapeutic use
Angiotensin-Converting Enzyme Inhibitors.therapeutic use
Animals
Hepatorenal Syndrome.physiopathology
Humans
Hypertension, Portal.drug therapy.physiopathology
Liver.drug effects
Liver Cirrhosis.drug therapy.physiopathology
Peptidyl-Dipeptidase A.metabolism
Renin-Angiotensin System.drug effects.physiology
Splanchnic Circulation.drug effects
Vasodilation.drug effects
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
22548407.pdf701.86 kBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.